MavriX Bio, a Penn startup company based on technology developed by James Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director’s Professor at Penn Medicine, received Fast Track designation from the FDA for MVX-220, an investigational gene therapy for Angelman Syndrome, a rare neurological disorder. Read more here.